Free Trial

Phreesia (NYSE:PHR) Trading Down 3.8% - What's Next?

Phreesia logo with Medical background

Phreesia, Inc. (NYSE:PHR - Get Free Report) shares traded down 3.8% on Friday . The company traded as low as $25.27 and last traded at $24.95. 72,553 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 452,030 shares. The stock had previously closed at $25.93.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wall Street Zen upgraded Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Truist Financial increased their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. KeyCorp increased their price target on shares of Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Canaccord Genuity Group lowered their price target on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a report on Thursday, May 29th. Finally, Citigroup reiterated a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.27.

Check Out Our Latest Stock Analysis on Phreesia

Phreesia Stock Performance

The stock has a 50 day simple moving average of $26.50 and a 200 day simple moving average of $26.40. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.51 billion, a P/E ratio of -34.38 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The business had revenue of $115.94 million for the quarter, compared to analysts' expectations of $115.00 million. During the same period last year, the firm posted ($0.05) earnings per share. The firm's quarterly revenue was up 14.5% compared to the same quarter last year. On average, equities analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Insider Activity at Phreesia

In other Phreesia news, SVP David Linetsky sold 23,729 shares of the business's stock in a transaction on Friday, June 27th. The shares were sold at an average price of $28.50, for a total transaction of $676,276.50. Following the sale, the senior vice president owned 193,510 shares of the company's stock, valued at approximately $5,515,035. The trade was a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael Weintraub sold 2,569 shares of the business's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $27.86, for a total value of $71,572.34. Following the sale, the director owned 143,039 shares in the company, valued at $3,985,066.54. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,240 shares of company stock valued at $1,329,816. Company insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Phreesia by 108.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock valued at $67,606,000 after acquiring an additional 1,377,904 shares during the last quarter. American Century Companies Inc. boosted its holdings in Phreesia by 3,741.9% in the first quarter. American Century Companies Inc. now owns 983,440 shares of the company's stock worth $25,137,000 after acquiring an additional 957,842 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of Phreesia by 133.6% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company's stock worth $31,999,000 after purchasing an additional 727,384 shares in the last quarter. Greenhouse Funds LLLP grew its holdings in shares of Phreesia by 27.9% during the fourth quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company's stock valued at $72,307,000 after buying an additional 626,579 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Phreesia during the 1st quarter valued at about $14,206,000. Institutional investors own 92.10% of the company's stock.

About Phreesia

(Get Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Recommended Stories

Should You Invest $1,000 in Phreesia Right Now?

Before you consider Phreesia, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.

While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines